Literature DB >> 9138151

Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.

K E Keating1, L Giblin, P J Lynch, K A Quane, M Lehane, J J Heffron, T V McCarthy.   

Abstract

Defects in the ryanodine receptor (RYR1) gene are associated with malignant hyperthermia (MH), an autosomal dominant disorder of skeletal muscle and one of the main causes of death resulting from anaesthesia. Susceptibility to MH (MHS) is determined by the level of tension generated in an in vitro muscle contracture test (IVCT) in response to caffeine and halothane. To date, mutation screening of the RYR1 gene in MH families has led to the identification of eight mutations. We describe here the identification of a novel mutation, Arg552Trp, in the RYR1 gene, which is clearly linked to the MHS phenotype in a large, well characterised Irish pedigree. Considering that the RYR1 protein functions as a tetramer, correlation of the IVCT with the affected and unaffected haplotypes was performed on the pedigree to investigate if the normal RYR1 allele in affected subjects contributes to the variation in the IVCT. The results show that the normal RYR1 allele is unlikely to play a role in IVCT variation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138151      PMCID: PMC1050914          DOI: 10.1136/jmg.34.4.291

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  25 in total

1.  Trinucleotide repeat polymorphism at the D19S190 locus.

Authors:  D E Iles; B Segers; P de Jong; J Alleman; B Wieringa
Journal:  Nucleic Acids Res       Date:  1992-03-11       Impact factor: 16.971

Review 2.  Malignant hyperthermia.

Authors:  D H MacLennan; M S Phillips
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

3.  Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia.

Authors:  E F Gillard; K Otsu; J Fujii; C Duff; S de Leon; V K Khanna; B A Britt; R G Worton; D H MacLennan
Journal:  Genomics       Date:  1992-08       Impact factor: 5.736

4.  A mutation in the human ryanodine receptor gene associated with central core disease.

Authors:  Y Zhang; H S Chen; V K Khanna; S De Leon; M S Phillips; K Schappert; B A Britt; A K Browell; D H MacLennan
Journal:  Nat Genet       Date:  1993-09       Impact factor: 38.330

5.  Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia.

Authors:  K A Quane; J M Healy; K E Keating; B M Manning; F J Couch; L M Palmucci; C Doriguzzi; T H Fagerlund; K Berg; H Ording
Journal:  Nat Genet       Date:  1993-09       Impact factor: 38.330

6.  Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q.

Authors:  R C Levitt; A Olckers; S Meyers; J E Fletcher; H Rosenberg; H Isaacs; D A Meyers
Journal:  Genomics       Date:  1992-11       Impact factor: 5.736

7.  Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein.

Authors:  A B Brillantes; K Ondrias; A Scott; E Kobrinsky; E Ondriasová; M C Moschella; T Jayaraman; M Landers; B E Ehrlich; A R Marks
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

8.  The point mutation Arg615-->Cys in the Ca2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia.

Authors:  K Otsu; K Nishida; Y Kimura; T Kuzuya; M Hori; T Kamada; M Tada
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

9.  The human ryanodine receptor gene: its mapping to 19q13.1, placement in a chromosome 19 linkage group, and exclusion as the gene causing myotonic dystrophy.

Authors:  A E MacKenzie; R G Korneluk; F Zorzato; J Fujii; M Phillips; D Iles; B Wieringa; S Leblond; J Bailly; H F Willard
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

10.  Biochemical evidence for a complex involving dihydropyridine receptor and ryanodine receptor in triad junctions of skeletal muscle.

Authors:  I Marty; M Robert; M Villaz; K De Jongh; Y Lai; W A Catterall; M Ronjat
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  5 in total

1.  Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families.

Authors:  V Barone; O Massa; E Intravaia; A Bracco; A Di Martino; V Tegazzin; S Cozzolino; V Sorrentino
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

2.  Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.

Authors:  B M Manning; K A Quane; H Ording; A Urwyler; V Tegazzin; M Lehane; J O'Halloran; E Hartung; L M Giblin; P J Lynch; P Vaughan; K Censier; D Bendixen; G Comi; L Heytens; K Monsieurs; T Fagerlund; W Wolz; J J Heffron; C R Muller; T V McCarthy
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

3.  Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.

Authors:  K Censier; A Urwyler; F Zorzato; S Treves
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

4.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

5.  Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness.

Authors:  Dorota Fiszer; Marie-Anne Shaw; Nickla A Fisher; Ian M Carr; Pawan K Gupta; Elizabeth J Watkins; Daniel Roiz de Sa; Jerry H Kim; Philip M Hopkins
Journal:  Anesthesiology       Date:  2015-05       Impact factor: 7.892

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.